Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome (2020)
Fonte: Journal of the american college of cardiology. Unidade: FM
Assuntos: SÍNDROME CORONARIANA AGUDA, LIPOPROTEÍNAS, ENZIMAS PROTEOLÍTICAS, LIPOPROTEÍNAS LDL, ESTATINAS, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
ABNT
BITTNER, Vera A et al. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. Journal of the american college of cardiology, v. 75, n. 2, p. 133-144, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2019.10.057. Acesso em: 16 maio 2024.APA
Bittner, V. A., Szarek, M., Aylward, P. E., Bhatt, D. L., Diaz, R., Edelberg, J. M., et al. (2020). Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. Journal of the american college of cardiology, 75( 2), 133-144. doi:10.1016/j.jacc.2019.10.057NLM
Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, Fras Z, Goodman SG, Halvorsen S, Nicolau JC. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome [Internet]. Journal of the american college of cardiology. 2020 ; 75( 2): 133-144.[citado 2024 maio 16 ] Available from: https://doi.org/10.1016/j.jacc.2019.10.057Vancouver
Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, Fras Z, Goodman SG, Halvorsen S, Nicolau JC. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome [Internet]. Journal of the american college of cardiology. 2020 ; 75( 2): 133-144.[citado 2024 maio 16 ] Available from: https://doi.org/10.1016/j.jacc.2019.10.057